Patricia’s commitment to the healthcare industry spans more than 25 years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc., a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson & Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZ-SCHATZ® balloon-expandable Stent, the first stent to achieve over a billion dollars in sales. Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University. She received the Distinguished Alumnus award from Pratt School of Engineering at Duke University in 2016.
Lori Bush joined the Viveve Board in May, 2016 with over 30 years of experience in the consumer and healthcare product industries. Ms. Bush served as President and CEO of Rodan + Fields from October, 2007 to May, 2016. During her tenure, the company re-launched under a transformative social commerce model and grew to become one of the largest premium skincare brands in the U.S. Prior to joining Rodan + Fields, she served as President of Nu Skin, the global personal care division of Nu Skin Enterprises and worked at Johnson & Johnson Consumer Products Companies as the Worldwide Executive Director over Skin Care Ventures. Lori also served as the Vice President of Professional Marketing for Neutrogena.
Lori is a frequent speaker at industry and academic events, has authored numerous papers on health, beauty, and women’s leadership and is co-author of a best-selling beauty and wellness book. Her passion and career driver has been developing integrated approaches to consumer health and beauty to help women live more satisfying lives. She earned her B.S. from The Ohio State University and M.B.A. from Temple University.
Dan Janney is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.
Dan is currently on the board of directors of several public and private companies, including Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (NASDAQ:VIVE). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President's Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.
Debora Jorn has served as a member of the Viveve board of directors since May, 2016. Ms. Jorn has 30 plus years of commercial experience building multi-billion dollar U.S. and global pharmaceutical and OTC businesses. Deb is a recognized leader in creating new markets and successfully launching products in numerous therapeutic areas. She is an expert commercial strategist who has led the consumer and physician marketing efforts for such iconic brands as Detrol LA, Ocuvite, Nasonex, Nuvaring, Jublia and Xifaxan. She also has an extensive background in several areas of Women’s Healthcare including overactive bladder, fertility, contraception, IBS-D and osteoporosis. Most recently, Deb was Executive Vice President and Group Company Chair at Valeant where she had responsibility for the Dermatology and Gastrointestinal businesses. Prior to that, she was the Chief Global Marketing Officer at Bausch & Lomb leading the prescription and OTC eye health business. Before joining Bausch & Lomb, Deb was the Group Vice President of Women’s Healthcare and Fertility at Schering Plough Corporation. She has a strong scientific background and extensive experience in all facets of the clinical development process leading to product launch including: market and competitive assessments, clinical strategy and trial design, labeling requirements for approval and competitive differentiation. PharmaVoice has recognized Ms. Jorn as “one of the top 100 most inspiring people in healthcare” in the “brand builders” category.
Arlene M. Morris joined the Viveve Board in May, 2016. Ms. Morris was previously the chief executive officer and president of Syndax Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers from April, 2012 to May, 2015 and a member of the board of directors from May, 2011 to June, 2015. Prior to Syndax, Arlene served as the president, chief executive officer and a member of the board of directors of Affymax, Inc. from 2003 to 2011, a publicly traded biotechnology company. She has held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. Arlene is currently a member of the board of directors of Neovacs, SA, a French publicly traded biotechnology company, Dimension Therapeutics, Biodel, Inc., and Palatin Technologies, Inc., all U.S. biopharmaceutical companies. She is also on the board of the Foundation for Research Development of the Medical University of South Carolina and previously served on the Board of BIO and the Humane Society of Silicon Valley. Ms. Morris received a B.A. in Biology from Carlow College.
Mr. Plexico is currently a managing member of Stonepine Capital Management, LLC. Previously, Mr. Plexico was managing director at Merriman Curhan Ford & Co., where he ran the healthcare corporate finance division focusing on private investments in public equity (PIPEs), secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life science advisor providing capital raising services to private biotechnology companies. Mr. Plexico served as director of business development at Chemdex Corporation, an electronic life-science commerce company that completed an initial public offering during his tenure. He began his career at Quidel Corporation, where he became national sales manager for the autoimmune division. Mr. Plexico is a graduate of Colgate University.